Tamar Bridge News is your trusted guide through the currents of UK news, committed to bridging the gap between information and insight with clarity, precision, and a human-centric approach.
Swisscann, a leading producer of premium medicinal cannabis products, has surpassed its £850,000 crowdfunding target on the UK-based Seedrs platform within just 24 hours. The Zurich-based company, which plans to enter the UK market in 2025, has also announced a significant European distribution deal with a publicly listed pharmaceutical firm, ensuring its products will soon be available across the continent. Swisscann’s cannabis-based treatments contain Tetrahydrocannabinol (THC), a cannabinoid increasingly prescribed for a variety of conditions including cancer, multiple sclerosis, Parkinson’s disease, and epilepsy. The products are also effective in managing symptoms such as inflammation, pain, nausea, muscle spasms, insomnia, anxiety,…